NO20082593L - Pyrazolo[4,3-D]pyrimidin-5-yl)derivater anvendt som PDE5 inhibitorer - Google Patents

Pyrazolo[4,3-D]pyrimidin-5-yl)derivater anvendt som PDE5 inhibitorer

Info

Publication number: NO20082593L
Authority: NO; Norway
Prior art keywords: pyrazolo; pyrimidin; derivatives used; pde5 inhibitors; methylpyridin
Prior art date: 2005-11-10

Application number

NO20082593A

Other languages

English (en)

Norwegian (no)

Inventor

Michael Brent Tollefson

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-11-10

Filing date

2008-06-10

Publication date

2008-07-22

2008-06-10 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2008-07-22 Publication of NO20082593L publication Critical patent/NO20082593L/no

Links

229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 title 1
-1 Pyrazolo [4,3-D] pyrimidin-5-yl Chemical group 0.000 title 1
239000002590 phosphodiesterase V inhibitor Substances 0.000 title 1
IQZQWPRZFLHJFI-UHFFFAOYSA-N 1-[1-(2-ethoxyethyl)-3-ethyl-7-[(4-methylpyridin-2-yl)amino]pyrazolo[4,3-d]pyrimidin-5-yl]piperidine-4-carboxylic acid Chemical compound C=12N(CCOCC)N=C(CC)C2=NC(N2CCC(CC2)C(O)=O)=NC=1NC1=CC(C)=CC=N1 IQZQWPRZFLHJFI-UHFFFAOYSA-N 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Gynecology & Obstetrics (AREA)
Psychiatry (AREA)
Addiction (AREA)
Psychology (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Pregnancy & Childbirth (AREA)
Child & Adolescent Psychology (AREA)

NO20082593A 2005-11-10 2008-06-10 Pyrazolo[4,3-D]pyrimidin-5-yl)derivater anvendt som PDE5 inhibitorer NO20082593L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US73532005P	2005-11-10	2005-11-10
PCT/IB2006/003132 WO2007054778A1 (en)	2005-11-10	2006-10-31	Pyrazolo[4,3-d]pyrimidin-5-yl)derivative used as pde5 inhibitors

Publications (1)

Publication Number	Publication Date
NO20082593L true NO20082593L (no)	2008-07-22

Family

ID=37685872

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20082593A NO20082593L (no)	2005-11-10	2008-06-10	Pyrazolo[4,3-D]pyrimidin-5-yl)derivater anvendt som PDE5 inhibitorer

Country Status (29)

Country	Link
US (2)	US20090156618A1 (sr)
EP (1)	EP1948661B1 (sr)
JP (1)	JP4208959B1 (sr)
KR (1)	KR101012592B1 (sr)
CN (1)	CN101305007B (sr)
AP (1)	AP2008004437A0 (sr)
AR (1)	AR057885A1 (sr)
AT (1)	ATE435865T1 (sr)
AU (1)	AU2006313486B2 (sr)
BR (1)	BRPI0618284A2 (sr)
CA (1)	CA2629339C (sr)
CR (1)	CR9966A (sr)
DE (1)	DE602006007728D1 (sr)
DK (1)	DK1948661T3 (sr)
DO (1)	DOP2006000248A (sr)
EA (1)	EA200800920A1 (sr)
EC (1)	ECSP088441A (sr)
ES (1)	ES2326919T3 (sr)
IL (1)	IL190456A (sr)
MA (1)	MA29943B1 (sr)
NL (1)	NL2000291C2 (sr)
NO (1)	NO20082593L (sr)
PE (1)	PE20070764A1 (sr)
RS (1)	RS20080197A (sr)
TN (1)	TNSN08209A1 (sr)
TW (1)	TW200738723A (sr)
UY (1)	UY29909A1 (sr)
WO (1)	WO2007054778A1 (sr)
ZA (1)	ZA200803173B (sr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2324020A2 (en) *	2008-08-01	2011-05-25	Biocryst Pharmaceuticals, Inc.	Piperidine derivatives as jak3 inhibitors
WO2010043633A1 (en) *	2008-10-15	2010-04-22	Palau Pharma, S. A.	2h-pyrazolo [4,3-d]pyrimidin-5-amine derivatives as h4 histamine receptor antagonists for the treatment of allergic, immunological and inflammatory diseases
JP2013523809A (ja) *	2010-04-05	2013-06-17	エスケーケミカルズカンパニーリミテッド	Ｐｄｅ５抑制剤を含む皮膚しわ改善用組成物
WO2012118042A1 (ja) *	2011-02-28	2012-09-07	独立行政法人国立循環器病研究センター	悪性腫瘍転移抑制用医薬
AU2012244550C1 (en)	2011-04-21	2017-06-22	Origenis Gmbh	Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
US9637491B2 (en)	2012-10-19	2017-05-02	Origenis Gmbh	Pyrazolo[4,3-D]pyrimidines as kinase inhibitors
CN104755086A (zh) *	2012-10-23	2015-07-01	辉瑞公司	四取代的吡唑并[4,3-d]嘧啶化合物用于治疗糖尿病肾病的用途
AU2015302271B2 (en)	2014-08-12	2019-02-28	Children’s Hospital of Philadelphia	Methods of improving myocardial performance in fontan patients using udenafil compositions
AU2020356193A1 (en)	2019-09-24	2022-05-19	Children's Hospital Of Philadelphia	Methods of improving exercise performance, single ventricular performance, and myocardial performance index (MPI) in single ventricle heart disease, using udenafil compositions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002514162A (ja)	1996-07-08	2002-05-14	デュポンファーマシューティカルズカンパニー	Ｘａ因子阻害薬およびトロンビン阻害薬としてのアミジノインドール類、アミジノアゾール類、およびそれらの類似体
EP1371647B1 (en)	1998-04-20	2005-07-13	Pfizer Inc.	Pyridine-3-carboxylic acid derivatives and their use as intermediates
GB9822238D0 (en) *	1998-10-12	1998-12-09	Pfizer Ltd	Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof
DE69911448T2 (de)	1998-10-23	2004-04-08	Pfizer Inc.	Pyrazolopyrimidinone, cgmp pde5 inhibitoren, zur behandlung von sexuellen funktionsstörungen
DE19942474A1 (de)	1999-09-06	2001-03-15	Merck Patent Gmbh	Pyrazolo[4,3-d]pyrimidine
RU2269523C2 (ru)	2000-04-28	2006-02-10	Акадиа Фармасьютикалз, Инк.	Мускариновые агонисты
DE10031584A1 (de)	2000-06-29	2002-01-10	Merck Patent Gmbh	5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine
WO2002016348A1 (en)	2000-08-09	2002-02-28	Astrazeneca Ab	Antiangiogenic bicyclic derivatives
ATE478872T1 (de)	2002-03-28	2010-09-15	Ustav Ex Botan Av Cr V V I I O	Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
EA008596B1 (ru) *	2003-04-29	2007-06-29	Пфайзер Инк.	5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
WO2004103407A2 (en)	2003-05-22	2004-12-02	Altana Pharma Ag	Composition comprising a pde4 inhibitor and a pde5 inhibitor
EP1687002A4 (en)	2003-11-10	2008-07-23	Synta Pharmaceuticals Corp	CONDENSED HETEROCYCLIC COMPOUNDS
GB0327319D0 (en) *	2003-11-24	2003-12-24	Pfizer Ltd	Novel pharmaceuticals
GB0327323D0 (en) *	2003-11-24	2003-12-31	Pfizer Ltd	Novel pharmaceuticals
DK1742950T3 (da) *	2004-04-07	2009-03-16	Pfizer Ltd	Pyrazolo-[4,3-D]-pyrimidiner
WO2006014325A2 (en)	2004-07-02	2006-02-09	Exelixis, Inc.	C-met modulators and method of use
JP2008517994A (ja) *	2004-10-28	2008-05-29	ファルマシア・アンド・アップジョン・カンパニー・エルエルシー	新規医薬品

2006
- 2006-10-27 NL NL2000291A patent/NL2000291C2/nl not_active IP Right Cessation
- 2006-10-31 JP JP2008539522A patent/JP4208959B1/ja not_active Expired - Fee Related
- 2006-10-31 AP AP2008004437A patent/AP2008004437A0/xx unknown
- 2006-10-31 BR BRPI0618284-4A patent/BRPI0618284A2/pt not_active Application Discontinuation
- 2006-10-31 DK DK06809195T patent/DK1948661T3/da active
- 2006-10-31 WO PCT/IB2006/003132 patent/WO2007054778A1/en not_active Ceased
- 2006-10-31 CN CN2006800416985A patent/CN101305007B/zh not_active Expired - Fee Related
- 2006-10-31 EA EA200800920A patent/EA200800920A1/ru unknown
- 2006-10-31 AT AT06809195T patent/ATE435865T1/de not_active IP Right Cessation
- 2006-10-31 EP EP06809195A patent/EP1948661B1/en active Active
- 2006-10-31 ES ES06809195T patent/ES2326919T3/es active Active
- 2006-10-31 DE DE602006007728T patent/DE602006007728D1/de active Active
- 2006-10-31 KR KR1020087011230A patent/KR101012592B1/ko not_active Expired - Fee Related
- 2006-10-31 AU AU2006313486A patent/AU2006313486B2/en not_active Ceased
- 2006-10-31 CA CA2629339A patent/CA2629339C/en not_active Expired - Fee Related
- 2006-10-31 RS RSP-2008/0197A patent/RS20080197A/sr unknown
- 2006-11-07 PE PE2006001379A patent/PE20070764A1/es not_active Application Discontinuation
- 2006-11-08 AR ARP060104894A patent/AR057885A1/es unknown
- 2006-11-09 UY UY29909A patent/UY29909A1/es not_active Application Discontinuation
- 2006-11-09 DO DO2006P000248A patent/DOP2006000248A/es unknown
- 2006-11-09 TW TW095141515A patent/TW200738723A/zh unknown
- 2006-11-09 US US11/558,306 patent/US20090156618A1/en not_active Abandoned
2008
- 2008-03-26 IL IL190456A patent/IL190456A/en not_active IP Right Cessation
- 2008-04-10 ZA ZA200803173A patent/ZA200803173B/xx unknown
- 2008-05-08 EC EC2008008441A patent/ECSP088441A/es unknown
- 2008-05-09 CR CR9966A patent/CR9966A/es not_active Application Discontinuation
- 2008-05-09 MA MA30918A patent/MA29943B1/fr unknown
- 2008-05-09 TN TNP2008000209A patent/TNSN08209A1/fr unknown
- 2008-06-10 NO NO20082593A patent/NO20082593L/no not_active Application Discontinuation
2010
- 2010-11-17 US US12/948,387 patent/US8518956B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
NL2000291C2 (nl)	2009-02-17
MA29943B1 (fr)	2008-11-03
AU2006313486A1 (en)	2007-05-18
KR20080063830A (ko)	2008-07-07
NL2000291A1 (nl)	2007-05-11
RS20080197A (sr)	2009-05-06
ES2326919T3 (es)	2009-10-21
JP2009519215A (ja)	2009-05-14
IL190456A0 (en)	2008-11-03
WO2007054778A1 (en)	2007-05-18
DE602006007728D1 (de)	2009-08-20
EP1948661B1 (en)	2009-07-08
CN101305007B (zh)	2011-07-20
US8518956B2 (en)	2013-08-27
CR9966A (es)	2008-06-16
CA2629339A1 (en)	2007-05-18
US20090156618A1 (en)	2009-06-18
AP2008004437A0 (en)	2008-04-30
BRPI0618284A2 (pt)	2011-08-23
KR101012592B1 (ko)	2011-02-07
ATE435865T1 (de)	2009-07-15
US20110059993A1 (en)	2011-03-10
ECSP088441A (es)	2008-06-30
HK1120803A1 (en)	2009-04-09
EA200800920A1 (ru)	2008-10-30
ZA200803173B (en)	2009-01-28
TNSN08209A1 (fr)	2009-10-30
TW200738723A (en)	2007-10-16
DOP2006000248A (es)	2007-10-15
AU2006313486B2 (en)	2011-10-27
JP4208959B1 (ja)	2009-01-14
EP1948661A1 (en)	2008-07-30
IL190456A (en)	2012-10-31
DK1948661T3 (da)	2009-09-07
AR057885A1 (es)	2007-12-26
UY29909A1 (es)	2007-06-29
CN101305007A (zh)	2008-11-12
PE20070764A1 (es)	2007-08-13
CA2629339C (en)	2010-07-27

Legal Events

Date	Code	Title	Description
2017-05-29	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20071915L (no)	2007-05-18	Diaminotriazolforbindelser nyttige som proteinkinaseinhibitorer
MXPA06011327A (es)	2006-12-15	Azaindoles utiles como inhibidores de jak y otras proteinas cinasas.
MX2010006748A (es)	2010-08-18	Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
IL184898A0 (en)	2007-12-03	Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
MX2009006700A (es)	2009-06-30	Derivados de 5-ciano-4-(pirolo)[2,3b]piridina-3-il)-pirimidinas utiles como inhibidores de proteina-cinasas.
MX2010008719A (es)	2010-09-24	Pirrolo [2,-d] piridinas y usos de las mismas como inhibidores de cinasa de tirosina.
UA95940C2 (uk)	2011-09-26	Азаіндоли як інгібітори кіназ януса
IL182893A0 (en)	2007-08-19	PYRAZOLO-[1,5-a] PYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
MY169791A (en)	2019-05-15	Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
NO20072567L (no)	2007-07-17	Triazoler nyttige som proteinkinase-inhibitorer
TW200604168A (en)	2006-02-01	Azaindoles useful as inhibitors of rock and other protein kinases
ATE430747T1 (de)	2009-05-15	2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
TN2011000247A1 (en)	2012-12-17	Organic compounds
UA105503C2 (uk)	2014-05-26	Похідні 1-аміно-2-циклобутилетилборонової кислоти
TW200744602A (en)	2007-12-16	Administration of dipeptidyl peptidase inhibitors
WO2007067506A3 (en)	2007-08-16	2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
MX2011009190A (es)	2011-09-26	Sales derivadas de tetrahidro-imidazo[1,5-a]piracina, metodos de preparacion y uso medicinal de las mismas.
ECSP088441A (es)	2008-06-30	Derivados de pirazolo [4,3-d]pirimidin-5-il usados como inhibidores de pde5
ATE542814T1 (de)	2012-02-15	Pyrazinkinaseinhibitoren
WO2007015923A8 (en)	2008-04-03	Benzimidazoles useful as inhibitors of protein kinases
UA87494C2 (en)	2009-07-27	Azaindoles useful as inhibitors of jak and other protein kinases
CY1115106T1 (el)	2016-12-14	Ενωσεις πυρρολο[2,3-d]πυριμιδινης